drugset
drugset / Trial / NCT00618696

Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia

NCT00618696 ↗

Phase 1 Terminated 4 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Radioactive monoclonal antibodies, such as yttrium Y 90 monoclonal antibody, can find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of a yttrium Y 90 monoclonal antibody and how much radiation is taken in by the organs in the body in treating patients with advanced leukemia or other hematologic disorder.

Timeline

Start
2005-07
Primary completion
2007-12
Completion
2007-12

Outcome

Outcome not reported

Stopped: “Replaced with another study”

Drugs

EvaluationDrugModalityDoseRoute
Subject AHN-12 Monoclonal antibody 150 mg/m2 Intravenous

Indications

leukemia myelodysplastic syndrome